
Opinion|Videos|July 10, 2024
Targeting Pathways Downstream of Dystrophin: Vamorolone and Givinostat in Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
Emma Ciafaloni, MD, discusses therapies for Duchenne muscular dystrophy that target pathways downstream of dystrophin, focusing on vamorolone and givinostat.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Discuss the efficacy and safety of vamorolone, a corticosteroid, which was FDA approved in 2023 for patients with Duchenne muscular dystrophy (DMD) aged 2 years and older.
- Where does givinostat, a pan-histone deacetylase inhibitor, that was FDA approved in 2024, fit in the treatment landscape of DMD?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Episode 153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines
2
NeurologyLive® Friday 5 — October 31, 2025
3
Zorevunersen’s Additive Efficacy in Patients on Established Antiseizure Medications
4
Evaluating Combined Supraorbital and Occipital Neuromodulation in Phase 3 Trial for Resistant Migraine: The RECLAIM Study
5
































